Vivos Therapeutics (VVOS) Competitors $3.15 -0.03 (-0.94%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$3.19 +0.04 (+1.27%) As of 10/15/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. EDAP, PSTV, VANI, ZJYL, LUNG, GUTS, ICCM, DXR, QTI, and MDAIShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Edap Tms (EDAP), Plus Therapeutics (PSTV), Vivani Medical (VANI), Jin Medical International (ZJYL), Pulmonx (LUNG), Fractyl Health (GUTS), IceCure Medical (ICCM), Daxor (DXR), QT Imaging (QTI), and Spectral AI (MDAI). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Its Competitors Edap Tms Plus Therapeutics Vivani Medical Jin Medical International Pulmonx Fractyl Health IceCure Medical Daxor QT Imaging Spectral AI Vivos Therapeutics (NASDAQ:VVOS) and EDAP TMS (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Which has more volatility and risk, VVOS or EDAP? Vivos Therapeutics has a beta of 6.9, indicating that its stock price is 590% more volatile than the S&P 500. Comparatively, EDAP TMS has a beta of -0.15, indicating that its stock price is 115% less volatile than the S&P 500. Which has better valuation and earnings, VVOS or EDAP? Vivos Therapeutics has higher earnings, but lower revenue than EDAP TMS. EDAP TMS is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivos Therapeutics$15.03M1.57-$11.14M-$1.68-1.88EDAP TMS$69.18M1.39-$20.58M-$0.61-4.23 Do analysts rate VVOS or EDAP? Vivos Therapeutics presently has a consensus price target of $4.92, indicating a potential upside of 56.08%. EDAP TMS has a consensus price target of $8.50, indicating a potential upside of 229.46%. Given EDAP TMS's higher probable upside, analysts plainly believe EDAP TMS is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00EDAP TMS 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to VVOS or EDAP? In the previous week, EDAP TMS had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 2 mentions for EDAP TMS and 1 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.95 beat EDAP TMS's score of 0.79 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vivos Therapeutics Positive EDAP TMS Positive Do insiders and institutionals hold more shares of VVOS or EDAP? 26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 62.7% of EDAP TMS shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 0.2% of EDAP TMS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is VVOS or EDAP more profitable? EDAP TMS has a net margin of -33.49% compared to Vivos Therapeutics' net margin of -99.49%. EDAP TMS's return on equity of -56.85% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vivos Therapeutics-99.49% -232.76% -84.30% EDAP TMS -33.49%-56.85%-26.83% SummaryEDAP TMS beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.86M$2.96B$6.12B$10.45BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-1.8822.7985.3327.36Price / Sales1.57778.19601.99136.95Price / CashN/A172.6337.4661.86Price / Book2.335.5112.566.81Net Income-$11.14M$33.06M$3.32B$276.80M7 Day Performance0.64%0.23%0.59%0.42%1 Month Performance-7.35%14.73%10.52%7.86%1 Year Performance24.51%-1.42%75.05%41.24% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics1.9057 of 5 stars$3.15-0.9%$4.92+56.1%+27.5%$23.86M$15.03M-1.88160EDAPEdap Tms2.8649 of 5 stars$2.20-3.9%$8.50+286.4%-6.2%$82.26M$69.18M-3.61230PSTVPlus Therapeutics3.9099 of 5 stars$0.82-7.7%$8.00+874.3%-51.8%$81.51MN/A-0.3720Analyst UpgradeVANIVivani Medical2.9935 of 5 stars$1.37-2.8%$4.00+192.0%+13.8%$81.16MN/A-3.0420Analyst ForecastZJYLJin Medical InternationalN/A$0.50-11.9%N/A-85.3%$78.27M$22.83M0.00245Gap UpHigh Trading VolumeLUNGPulmonx3.5603 of 5 stars$1.73-0.6%$7.66+343.0%-76.9%$70.49M$90.55M-1.21250News CoverageGUTSFractyl Health3.208 of 5 stars$1.37-6.8%$6.90+403.6%-43.9%$68.90M$17K-0.67102Positive NewsGap UpHigh Trading VolumeICCMIceCure Medical3.2445 of 5 stars$1.000.0%$2.64+163.5%+48.3%$68.69M$3.29M-6.2560Gap UpHigh Trading VolumeDXRDaxor3.7831 of 5 stars$13.45-2.6%$25.00+85.9%+41.1%$65.06M$3.31M0.0037Gap DownQTIQT ImagingN/A$2.39+2.5%N/A+258.3%$64.85M$4.00M0.00N/AGap DownMDAISpectral AI2.9739 of 5 stars$2.38-1.7%$3.50+47.1%+109.5%$63.62M$27.55M-3.4583High Trading Volume Related Companies and Tools Related Companies Edap Tms Competitors Plus Therapeutics Competitors Vivani Medical Competitors Jin Medical International Competitors Pulmonx Competitors Fractyl Health Competitors IceCure Medical Competitors Daxor Competitors QT Imaging Competitors Spectral AI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
